Shares of Biontech (BNTX.US), which together with Pfizer (PFE.US) developed revolutionary mRNA vaccines during the pandemic, are gaining 5% as its Q1 report beat Wall Street analysts' estimates. The company exceeded expectations in both revenue and earnings. Of course, on a year-over-year basis, results deteriorated significantly but not at the scale and pace estimated by Wall Street. Recently, analysts were also positively surprised by Moderna's (MRNA.US) reports. Have investors been 'too brutal' for vaccine makers?
Revenues: €1.28 billion vs. €1.12 billion forecasts
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appEarnings per share (EPS): EUR 2.05 vs. EUR 0.69 forecasts
Operating profit: €654 million vs. 231.8 million forecasts
- The company reiterated its forecast of €5 billion in revenue through covid vaccines, and maintained its forecast of R&D spending between €2.4 billion and €2.6 billion in 2023;
- It wants to expand its line of vaccines against infectious diseases by starting the clinical phase for the first mRNA-based vaccine against tuberculosis;
- Biontech is also focusing on the development of more, next-generation products ahead of the fall and winter seasons. Together with OncoC4, it plans to initiate a Phase 3 clinical trial evaluating the anti CTLA-4 antibody BNT316 (ONC-392) in patients with NSCLC;
- The company plans to introduce a new class of precision therapies to its oncology portfolio. It will also present clinical data of BNT316 (ONC-392), ADC candidate BNT323 (DB-1303) and CAR-T candidate BNT211 at the American Society of Clinical Oncology conference in 2023;
- Biontech now wants to focus primarily on treating cancer and infectious diseases but the company's CEO, Ugur Sahin, signaled that Biontech is ready to continue developing vaccines against covid;
- Both Biontech and Moderna have a small amount of debt 'fueling' the business, and the huge amount of cash accumulated during the vaccine boom may favor higher spending on R&D (technological and possibly quality advances) and enlarging the advantage over smaller competitors.
Biontech (BNTX.US) shares, D1 interval. Shares have fallen nearly 80% from peak valuations near $500, in 2021. The company is now trading roughly 200% above its March 2020 price. Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
